The agreement in principle mentioned that there would be added to the litigation system a right of appeal that the European Union on behalf of brand name pharmaceutical companies had asked for. In the technical document and in our other discussions with the government, they've committed to revamping the system in entirety, that is, what we call the patent linkage system for pharmaceuticals in Canada. It's a very complicated system. It blocks the generic approval at Health Canada until there's litigation determining whether a patent is infringed or not. So you're blocked.
When the generic is successful, there are still full patent rights to sue a generic under the Patent Act. What we're finding is an excessive amount of patent litigation delaying generics, adding to our cost, and adding to the cost of the brand name companies. So I think that simplifying this system and unifying this system will be a very important measure and it's something that we are looking forward to developing with the government.